PROK - NASDAQ

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%

HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$581.72M

EPS-0.5200

P/E Ratio-3.33

Earnings Date08/06/2026

335.57M

Assets

-24%

3Y-35.0%

5Y+1909.0%

10Y+1612.0%

34.78M

Total Liabilities

-12%

3Y+166.0%

5Y+409.0%

10Y+834.0%

300.79M

Total Equity

-25%

3Y-40.0%

5Y+2949.0%

10Y+1794.0%

ProKidney Corp. Funding & Solvency Profile

PROK · NASDAQ

Current Assets

Cash & Cash Equivalents108.54M

Net Receivables1.13M

Inventory0.00

Other Current Assets9.54M

Total Current Assets281 M

Non-Current Assets

Property, Plant & Equipment54.90M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets55 M

Total Assets

335.57M

Financial Health Analysis

Current Ratio

9.13x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

250 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

84% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ProKidney Corp. Balance Sheet

PROK • NASDAQ

ProKidney Corp. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	108.5M	99.1M	60.6M	490.3M	20.6M	4.6M	15.2M
Short-Term Investments	161.5M	259.2M	302.3M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	270M	358.3M	363M	490.3M	20.6M	4.6M	15.2M
Net Receivables	1.1M	2.4M	1.4M	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	2.4M	1.4M	0.0	0.0	0.0	0.0
Other Receivables	1.1M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	15.7M	9.8M	13.1M	6.7M	955K	198K
Other Current Assets	9.5M	19.4M	9K	1.4M	25K	52K	0.0
Total Current Assets	280.7M	395.9M	374.1M	504.7M	27.3M	5.6M	15.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	54.9M	45.2M	46.4M	13.1M	12.6M	10.5M	3.3M
Goodwill	0.0	0.0	0.0	0.0	0.0	641.4K	0.0
Intangible Assets	0.0	0.0	0.0	213K	428K	642.0	857K
Goodwill & Intangible Assets	0.0	0.0	0.0	213K	428K	642K	857K
Total Non-Current Assets	54.9M	45.2M	46.4M	13.3M	13M	11.1M	4.2M
Total Assets	335.6M	441.1M	420.6M	518M	40.3M	16.7M	19.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	940K	4.3M	6.6M	3M	2.8M	781K	480K
Accounts Payable	940K	3.6M	5.1M	3M	2.8M	781K	480K
Other Payables	0.0	682K	1.5M	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	19.7M	10.1M	7.3M	9.2M	2.8M	1.8M
Capital Lease Obligations (Current)	0.0	765K	803K	493K	267K	225K	102K
Tax Payables	1.1M	682K	1.5M	278K	0.0	0.0	0.0
Other Current Liabilities	29.8M	11.5M	7.5M	0.0	0.0	1.7M	355K
Total Current Liabilities	30.7M	36.2M	25M	10.9M	12.3M	5.5M	2.7M
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	1.1M	748K	568K	278K	0.0	0.0	0.0
Total Non-Current Liabilities	4M	3.2M	4.2M	2.2M	1.1M	1.3M	1M
Capital Lease Obligations	3M	3.2M	4.4M	2.4M	1.3M	1.6M	1.1M
Total Liabilities	34.8M	39.4M	29.2M	13.1M	13.4M	6.8M	3.7M
SHAREHOLDERS' EQUITY
Common Stock	30K	29K	23K	24K	188.4M	116.2M	95.5M
Additional Paid-In Capital	258.6M	205.7M	36.1M	7.5M	0.0	0.0	0.0
Retained Earnings	-1.3B	-1.2B	-1.1B	-1.1B	-161.5M	-106.4M	-79.6M
Accumulated Other Comprehensive Income/Loss	56K	130K	130K	0.0	0.0	0.0	0.0
Total Stockholders' Equity	-1B	-995M	-1.1B	-1.1B	26.9M	9.9M	15.9M
Total Equity	300.8M	401.6M	391.3M	504.9M	26.9M	9.9M	15.9M
Minority Interest	1.3B	1.4B	1.5B	1.6B	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	335.6M	441.1M	420.6M	518M	40.3M	16.7M	19.6M
Total Investments	161.5M	259.2M	302.3M	0.0	0.0	0.0	0.0
Total Debt	3M	3.2M	4.4M	2.4M	1.3M	1.6M	1M
Net Debt	-105.6M	-95.9M	-56.2M	-487.9M	-19.2M	-3M	-14.2M
Shares Outstanding	131,750,000	131,750,000	131,750,000	131,750,000	131,750,000	131,750,000	131,750,000

SEC Filings

PROK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 02, 2026	February 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 10, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 98 filings

Related Guides

Blog Categories

Continue your PROK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.